Purpose: Insulin/insulin receptor (INSR) signaling plays diverse roles in the central nervous system, including regulation of blood glucose, synaptic plasticity, dendritic growth, modulation of electrophysiological activity, proliferation of astrocytes and neuronal apoptosis. Interestingly, many of these and/or related processes represent biological mechanisms associated with temporal lobe epilepsy (TLE). Thus, insulin signaling may play a role in the development of TLE and its therapeutic responses. We hypothesized that functional polymorphisms in the insulin pathway genes INSR, insulin receptor substrate 1 (IRS1), and IRS2 may be associated with the therapeutic responses of TLE. Therefore, in this study we analyzed the association of three single nucleotide polymorphisms (SNPs) showing a risk for TLE drug resistance using a hospital-based case-control design. Method: Two hundred and one patients with refractory TLE and one hundred and seventy-five drugresponsive TLE patients were recruited for the study. Polymerase chain reaction-restriction fragment length polymorphism was used to detect the genotypes of INSR His1085His, IRS1 G972R and IRS2 1057G/A. Results: No significant differences between refractory and drug-responsive TLE patients were observed for the IRS1 G972R and IRS2 1057G/A polymorphisms (P > 0.05), but a significant association was found for the INSR His1085His polymorphism for both genotypes (P = 0.035) and alleles (P = 0.011). IRS2 1057G/A combined with the INSR His1085His polymorphism increased the odds ratio of drug resistance in TLE (P = 0.011, OR = 2.263, 95% CI: 1.208-4.239). Conclusion: These results suggest that a genetic variation in the insulin signaling pathway genes may affect the therapeutic response of TLE.
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Methods

Patients
The study was performed between July 2012 and April 2014 with the approval of the ethics committee at Shandong University. All subjects voluntarily participated in this study. Written informed consent was obtained from all subjects following a complete description of the study. The study consisted of 201 patients with drug-resistant TLE and 175 patients with drug-responsive TLE. All TLE subjects who had been receiving antiepileptic drug treatment for at least two years were diagnosed and recruited by physicians in the Neurology Department of Linyi People's Hospital. The criteria for TLE diagnosis were based upon the 1989 ILAE's clinical classification. Among all the patients, refractory TLE was defined as four or more seizures over a 4-week period during the previous year, when receiving two or more appropriate and sufficient doses of antiepileptic drugs. Non-refractory epilepsy was defined as the absence of seizures for at least a one-year period. Seizure frequency was self-reported by the patients and their family members, and averaged for each month over the previous 6 month period. Venous blood samples (5 mL) were taken for DNA extraction and genotyping. Subject information and genotype data were identified by a code to ensure that the genotyping was performed blind.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using standard methods. All polymorphisms were genotyped by the polymerase chain reaction (PCR)-restriction fragment length polymorphism method. Genotyping of the INSR H1085H C>T, IRS1 G972R and IRS2 1057G/A was conducted by polymerase chain reaction (PCR), followed by the appropriate restriction enzyme digestion (PCR-restriction fragment length polymorphism [RFLP]). Primer sequences and conditions for PCR-RFLP analyses are presented in Supplementary Table S1 . DNA fragments were electrophoresed in 3% agarose gels.
Statistical analysis
Deviation from the Hardy-Weinberg equilibrium (HWE) and differences in allele and genotype distributions were assessed using the x 2 test or Fisher's exact test where appropriate.
Quantitative traits were accessed by t-test. The effect of genegene interaction was tested using binary logistic regression analysis. The odds ratio (OR) was calculated with a 95% confidence interval (95% CI). All tests were performed at a level of significance of 5% (P < 0.05).
Results
Demographic and clinical variables of the subjects are summarized in Supplementary Table S2 . Refractory and drugresponsive TLE subjects show significant differences with respect to the age at seizure onset, duration of epilepsy, and hippocampal sclerosis rates.
Genotypic and allelic distributions for INSR H1085H C>T, IRS1 G972R and IRS2 1057G/A polymorphisms are summarized in Table 1 . Distributions of genotypic frequencies for the three polymorphisms were in the Hardy-Weinberg equilibrium. No significant differences were detected in genotypic or allelic frequencies at IRS1 G972R and IRS2 1057G/A between refractory and drug-responsive TLE subjects. The genotypic distribution of the His1085His polymorphism differed significantly (P = 0.035) between the refractory and drug-responsive TLE groups. Further analyses showed that the His1085His ''T'' allele frequency accumulated in refractory TLE subjects (36.1%) to a greater extent as compared with drug-responsive TLE subjects (27.4%), suggesting a significant involvement of the His1085His ''T'' allele as a probable independent risk factor for refractory TLE (P = 0.011, OR = 1.493, 95% CI: 1.094-2.037). Table 2 shows the gene-gene interaction of INSR H1085H C>T, IRS1 G972R and IRS2 1057G/A in TLE. To assess all possible gene interactions, nine possible combinations as shown in the table were chosen for analyses. Logistic regression analysis was performed as a means to determine whether the presence or absence of either variant allele of INSR H1085H C>T, IRS1 G972R and IRS2 1057G/A alone or in combinations could alter the odds ratio of drug resistance. With combinations of INSR H1085H C>T and IRS2 1057G/A (INSR CT + TT and IRS2 GA + AA were present), we found odds ratios of 2.263 fold. These data were also analyzed Data presented as number of subject (percentage).
after adjusting for gender and age. Little difference was found between the adjusted and unadjusted data, which failed to differ significantly (data not shown).
Discussion
Exon 17 encodes the partial tyrosine kinase domain containing the ATP binding site of INSR, which is a key factor in phosphorylation during autophosphorylation responses.
6 IRS1
Gly972Arg and the IRS2 Gly1057Asp SNPs were selected for analysis due to their putative effects on p85 and GRB2 binding, which result in impaired signaling. 7 Our results suggest that the His1085His ''T'' allele and the CT + TT genotypes of INSR may be associated with refractory TLE susceptibility. The His1085His ''T'' allele frequency was significantly higher in patients with refractory TLE than in drug-responsive TLE subjects. Moreover, an analysis of gene-gene interactions of the INSR H1085H C>T and IRS2 1057G/A polymorphisms provides further support that the His1085His ''T'' allele may contribute to the etiology of refractory TLE. Taken together, these results suggest that a specific set of polymorphic genes in the insulin signaling pathway have the potential to influence therapeutic responses in TLE.
The possible relationship between insulin/INSR signaling and TLE is also supported by previous experimental data. For example, INSRs are widely expressed in the brain and insulin-bound insulin receptor activates IRS1 and IRS2, which can then bind to the p85 subunit of the phosphatidylinositol (PI)-3 kinase and activate the serine kinase PKB/Akt pathway to regulate apoptosis and glucose metabolism. Moreover, there are data which suggest that glycemic modulation can alter seizure thresholds and reduce the extent of seizure-induced cell death following kainate administration 8 ; and, insulin has been shown to inhibit hippocampal epileptiform-like activity. 9 Emerging evidence suggests an important role for insulin signaling in synaptic plasticity by modulating the surface expression of N-methyl-D-aspartate, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and g-aminobutyric acid (GABA) A receptors, 1,9,10 and modulating glutamatergic 10 and GABAergic 1 synaptic transmission in the hippocampus. As synaptic plasticity has been linked with neural network reorganization, 11 the recurrence of seizures may cause abnormal network reorganization, thus contributing to TLE.
12
In conclusion, our results suggest INSR CT or TT genotype carriers have an increased risk for developing refractory TLE. The risk effect was even stronger among carriers with both the INSR (CT or TT) and the IRS2 (GA or AA) genotypes. Further studies with other independent samples sets will be required to confirm the findings of this report. Data presented as number of subject (percentage).
